Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction to Virus01:28

Introduction to Virus

976
Viruses are unique biological entities that blur the boundary between living and non-living systems. Although they lack cellular structure and metabolic processes, they can exhibit characteristics of life when infecting a host. Their defining feature is a nucleic acid core, composed of either DNA or RNA, encapsulated within a protein coat called a capsid. This simple structure allows them to invade host cells and use their machinery for replication efficiently.Viral Structure and...
976
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

49.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.0K
Subviral Agents01:29

Subviral Agents

391
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
391
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

605
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
605
What are Viruses?00:50

What are Viruses?

127.1K
Overview
127.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A two-step centrifugal microfluidic platform for semi-automated IGRA detection of tuberculosis based on chemiluminescence.

The Analyst·2026
Same author

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.

Viruses·2026
Same author

Molecular basis of host ATP level modulation by actin-dependent secreted bacterial ATPase and its metaeffector.

Nature communications·2026
Same author

Structural basis and immunogenic efficacy of porcine circovirus type 3 virus-like particle.

Nature communications·2026
Same author

Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia.

Signal transduction and targeted therapy·2026
Same author

An All-in-One Microfluidic Platform for POCT-Ready Nucleic Acid Extraction from Heterogeneous Clinical Samples.

Analytical chemistry·2026
Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026
Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026
Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026
Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026
Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.6K

Recent Progress on the Versatility of Virus-Like Particles.

Ciying Qian1, Xinlin Liu1, Qin Xu1

  • 1National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Life Sciences, Xiamen University, Xiamen 361102, China.

Vaccines
|April 5, 2020
PubMed
Summary
This summary is machine-generated.

Virus-like particles (VLPs) are safe, non-infectious viral mimics. These nanostructures offer versatile applications in vaccinology and biomedicine due to their excellent immunogenicity and drug delivery capabilities.

Keywords:
nanocarrierrecombinant vaccinevirus-like particles

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.6K

Related Experiment Videos

Last Updated: Dec 25, 2025

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting
08:40

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

59.6K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

4.1K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.6K

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Immunology

Background:

  • Virus-like particles (VLPs) are virus-based nanostructures lacking genetic material.
  • VLPs mimic natural viruses in morphology but are non-pathogenic and non-infectious.
  • They are emerging as safe alternatives to traditional vaccines.

Purpose of the Study:

  • To review the diverse applications of VLPs in modern science.
  • To highlight VLP potential in antigen presentation, drug delivery, and vaccine development.
  • To underscore VLPs as powerful tools in vaccinology and biomedical research.

Main Methods:

  • This review synthesizes existing research on VLP applications.
  • Key VLP characteristics such as morphology, immunogenicity, and targeting are discussed.
  • The role of VLPs as nanocarriers is examined.

Main Results:

  • VLPs demonstrate effective tissue-specific targeting and cell penetration.
  • Highly ordered epitope repeats on VLPs elicit strong immune responses (cellular and humoral).
  • VLPs serve as effective platforms for displaying antigenic epitopes and delivering small molecules.

Conclusions:

  • VLPs are versatile nanocarriers with significant potential in vaccine technology.
  • Their inherent safety and immunogenicity make them ideal for developing novel vaccines.
  • VLPs represent a powerful and adaptable platform for advancing biomedical research and therapeutic strategies.